TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$288 Million

Kronos Bio

Initial Public Offering

Bookrunner, October 2020

Kronos Bio

Kronos Bio, Inc. is a clinical-stage biopharma company developing cancer therapeutics targeting dysregulated transcription through a precision medicine strategy. Its proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity. The Company’s lead product candidate, ENTO, is a selective inhibitor targeting spleen tyrosine kinase (SYK), a critical node in a dysregulated TRN within acute myeloid leukemia (AML) defined by persistent high expression of the transcription factors HOXA9 and MEIS1 (HOX/MEIS). The Company’s second product candidate, KB-0742, was generated from the Company’s small molecule microarray platform. KB-0742 is an orally bioavailable inhibitor of CDK9, a global regulator of transcription and a critical node in the oncogenic TRN resulting from MYC overexpression.